Orthobiologics treatment helps healing procedure of different injured muscles, fractures, ligaments, tendons, and more with the help of the naturally occurring substances in the human body, known as orthobiologics. Particularly, orthobiologics comprise the growth factors, stem cells, (PRP) the platelet-rich-plasma, the conditioned serum, autologous blood, and the bone grafts. All these elements or substances are naturally occur in the body. The domain of orthobiologics is today, speedily gaining popularity and is also expanding. It allows the human body to recreate itself via countless treatment alternatives available that previously were either extremely painful or also not very effective. Hence, considering the contemporary orthobiological procedure available today, the recovery is comparatively faster and patients report returning back to their normal lives with no injury and better physical state.
Orthobiologics market was valued at over US$ 5.5 Bn. in 2017. It is anticipated to grow at a CAGR of 5.2% from 2019 to 2030.
The growth of this market can be attributed to the factors such as, increase in sports injuries and road accidents, awareness among patients & athletes, rise in obesity rate, and continuously aging population. According to the World Health Organization, 2017, fatal road accidents are the second primary cause of factures and accidental injury worldwide with almost 646000 individuals die every year around the world.
Major Key Players of the Orthobiologics Market are:
Medtronic, DePuy Synthes, Zimmer Biomet, MTF, Sanofi, Bioventus, Arthrex, Seikagaku and NuVasive among others.
No comments:
Post a Comment